3 Hrs
Source:
صحة
صحة
Ready to play
Ready to play
On November 9, 2026, the U.S. Food and Drug Administration required companies to add a warning about non-arteritic anterior ischemic optic neuropathy to the prescribing information for GLP-1 drugs, including Ozempic, Wegovy, and Mounjaro. The agency emphasized that the warning does not mean the drugs are banned or that vision loss is inevitable. The analysis covered 126 trials and more than 134,000 participants. The rate was 6.4 cases per 100,000 person-years among users of these drugs, compared with 3.8 cases in the comparison group. The agency advised seeking medical care immediately in the event of sudden, painless vision loss or visual disturbances, and discussing whether to continue or stop treatment with a doctor if the condition is suspected or confirmed.
Notice: This Is an AI-Generated Summary
Comments (0)